Physician profile
Monica E M Eccles
NPI 1134683071
$2,112.81
in general payments reported to CMS, 2019-2025
15 companies · $99.18 in 2025
The $99.18 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $248 · 2022: $593 · 2023: $621 · 2024: $552 · 2025: $99.18.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,272.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,272.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $713.61 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $245.74 | 2022-2025 | Tezspire, Airsupra, Farxiga |
| Lilly USA, LLC | $188.50 | 2021-2024 | Mounjaro, Zepbound |
| Abbott Laboratories | $172.80 | 2022-2023 | Freestyle Libre 2 |
| Idorsia Pharmaceuticals US INC | $139.17 | 2023 | Quviviq |
| Esperion Therapeutics, INC. | $124.98 | 2021 | |
| Grifols USA, LLC | $117.17 | 2024 | Hyperrab |
| Pfizer INC. | $99.12 | 2021-2025 | |
| Amgen INC. | $83.47 | 2023-2024 | Otezla, Repatha |
| Glaxosmithkline, LLC. | $82.72 | 2022 | |
| Novo Nordisk INC | $75.13 | 2022-2024 | Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $19.31 | 2024 | Gardasil 9, Gardasil, Capvaxive |
| Vertex Pharmaceuticals Incorporated | $18.25 | 2025 | |
| Amarin Pharma, INC. | $17.52 | 2021 | |
| Sanofi-Aventis U.S. LLC | $15.32 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Monica Eccles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.